NCT05369676View on ClinicalTrials.gov

To Evaluate SSD8432/ Ritonavir in Adults With COVID-19

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

August 29, 2022

Study Completion Date

August 29, 2022

Conditions
COVID-19 Patients
Interventions
DRUG

SSD8432 dose 1/Ritonavir

Cohort 1:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；

DRUG

SSD8432 dose 2/Ritonavir

Cohort 2:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；

Trial Locations (1)

518100

Shenzhen Third People's Hospital, Shenzhen

Sponsors
All Listed Sponsors
lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY

NCT05369676 - To Evaluate SSD8432/ Ritonavir in Adults With COVID-19 | Biotech Hunter | Biotech Hunter